23 February 2018

ENHANCING HONG KONG'S LISTING FRAMEWORK

Consultation on Listing Regime for Companies from Emerging and Innovative Sectors



Charles Li David Graham James Fok Grace Hui




1

Background to the Consultation









BACKGROUND TO THE CONSULTATION



What Did We Set Out to Achieve?

OUR GOAL:



Enhance Hong Kong's competitiveness as a global financial centre



Attract high growth companies from emerging and innovative sectors



Diversify Hong Kong's market

Issues Identified



No regime for pre-revenue emerging and innovative companies



No regime for non-standard governance features



Restrictions on secondary listings



Proposed Way Forward Following "New Board" Concept Paper Feedback





What Has Been Done Since Publication of the "New Board" Consultation Conclusions in December 2017?



Engaged with practitioners

- Feedback on appropriate listing parameters / conditions / safeguards / requirements
- Specialist advice on Biotech Companies



Engaged with issuers


- Better understanding of real issues / market needs
- Ensure listing regime is globally competitive



Detailed regulatory discussion

- SFC → appropriate investor protections
- Listing Committee → detailed Listing Rules requirements and practical operation of the new regime







CONSULTATION PROPOSALS



Contents of This Consultation

Proposals





CONSULTATION PROPOSALS BIOTECH CHAPTER



Principles Underlying Biotech Issuer Suitability



Product regulated by Competent Authority

- US Food and Drug Administration (FDA), China Food and Drug Administration (CFDA), European Medicines Agency (EMA)
- Other authorities will be considered on a case-by-case basis



Past concept stage

- Completed Phase I and received no objection to commence Phase II (or later)
- Product subject to human testing



Meaningful investment from at least one Sophisticated Investor

• To provide a level of validation from an experienced third party investor



Proposed Listing Eligibility

SUITABILITY FOR LISTING -

PRODUCT At least one Core Product⁽¹⁾ beyond concept stage

RESEARCH AND DEVELOPMENT

Primarily engaged in R&D of its Core Product(s) for a minimum of 12 months

IPO

Primary reason for listing is to raise capital for R&D to bring its Core Product(s) to commercialisation

PATENTS

Durable patent(s), registered patent(s), patent application(s) and/or intellectual property in relation to its Core Product(s)

SOPHISTICATED INVESTOR⁽²⁾

Meaningful investment⁽³⁾ for at least 6 months before IPO (which must remain at IPO)

Specific guidance for Biotech Issuers

Pharmaceutical (small molecule drugs)

- completed Phase I or, for previously approved products (e.g. FDA's 505(b)(2)) – at least one trial on human subjects; and
- no objection to commence Phase II

Biologics

- completed Phase I, or for biosimilar at least one trial on human subjects; and
- no objection to commence Phase II (or later)

Medical Devices (including diagnostics)

- Class II medical device (or equivalent) or above;
- at least one trial on human subjects;
- endorsed or no objection to proceed to further clinical trials or commence sales of the device

Other Biotech Products

- will be considered on a case-by-case basis;
- need to demonstrate it is beyond concept stage;
- appropriate framework or objective indicator for investors to make an informed investment decision


11

- (1) A Biotech Product(s) that is required by applicable laws, rules or regulations to be evaluated and approved by a Competent Authority based on data derived from clinical trials (i.e. on human subjects) before it could be marketed and sold in the market regulated by that Competent Authority which forms the basis of a Biotech Company's listing application under Chapter 18A of the Listing Rules
- (2) By reference to factors such as net assets or assets under management, relevant investment experience, and the investor's knowledge and expertise in the relevant field

(3) Being more than just a token investment

Additional Listing Requirements and Shareholder Protections

Сар	■ ≥HK\$1.5billion
Track Record	 In its current line of business for at least 2 financial years Substantially the same management
Working Capital	 125% of the group's costs for at least next 12 months (after taking into account the proceeds of the IPO) Must substantially consist of (a) general, administrative and operating costs; and (b) R&D costs
Restriction on Cornerstones	 Cornerstones will not count towards minimum initial public float requirement at listing or during 6 months lock-up Existing pre-IPO investors can participate in IPO and only IPO shares subscribed for will not count towards minimum initial public float requirement
Special Measures to Manage Risks	 Fundamental change of principal business will require consent from the Exchange Accelerated de-listing process (12 months to re-comply with requirement) Stock marker "B" at the end of its stock name



CONSULTATION PROPOSALS WVR CHAPTER



Proposed Listing Eligibility



NEW APPLICANTS ONLY

HIGH MARKET CAP.

■ ≥HK\$10bn with ≥HK\$1bn in revenue if <HK\$40bn

INNOVATIVE

as defined by guidance

SUCCESSFUL

track record of high business growth

EXTERNAL VALIDATION

meaningful third party investment

WVR BENEFICIARIES

INDIVIDUALS ONLY

- materially responsible for growth of the business
- separate consultation on corporate beneficiaries

DIRECTORS ONLY

at listing and afterwards

SHAREHOLDING

≥10% and ≤50% at listing (collectively)

TRANSFERS PROHIBITED

- natural sunset
- allow trusts and legitimate tax planning

Additional Listing Requirements and Shareholder Protections

- No increase in proportion of WVRs after listing
- Share-based WVR only with maximum 10x voting power vs. ordinary shares
- Non-WVR shareholders must have 10% of voting power
- Fundamental matters voted on a "one-share, one-vote" basis
 - changes to constitutional documents;
 - INED appointment & removal;
 - auditor appointment & removal;
 - variation of rights attached to any class of shares; and
 - voluntary winding-up of the listed issuer

Enhanced disclosure

- Warnings on listing documents and communications
- "W" stock marker

Enhanced corporate governance


- Corporate governance committee to review, monitor and report on compliance with WVR safeguards
- Ongoing compliance adviser to provide advice to issuers on compliance with WVR safeguards and rules

Constitutional backing and legal remedies

- WVR safeguards must be incorporated into constitutional documents
- WVR beneficiaries must give undertaking to the issuer to comply with WVR safeguards



SAFEGUARDS



CONSULTATION PROPOSALS SECONDARY LISTING CHAPTER



Qualifying Criteria for New Secondary Listing Regime





Secondary Listing of Qualifying Issuers

GRANDFATHERED

GREATER CHINA COMPANIES

NON-GRANDFATHERED GREATER CHINA COMPANIES NON-GREATER CHINA COMPANIES

GRANDFATHERED GREATER CHINA COMPANIES:

- Greater China companies that primary listed on a Qualifying Exchange on or before 15 Dec 2017
- Must demonstrate how they are subject to Key Shareholder Protections⁽¹⁾ (changes to constitutional documents may be required, as necessary)
- No need to comply with ongoing primary Listing Rule requirements (e.g. notifiable transaction and connected transaction rules)
- Can secondary list with their existing WVR structures and VIE structures intact (if they have them)
- No need for them to comply with WVR safeguards (other than those requiring disclosure)
- If "bulk of trading" moves permanently to Hong Kong then primary Listing Rule requirements would apply but not WVR safeguards (other than disclosure requirements)



(1) For example:

- issuer must hold an annual general meeting at least every 15 months, give reasonable notice of meetings and members to have the right to speak and vote at the shareholders' meeting
- super-majority vote of members is required to approve fundamental matters (material changes to constitutional documents, variation of rights attached to any class of shares and voluntary winding-up)
- · appointment, removal and the remuneration of auditors require the approval of a majority of shareholders or other body independent of the board of directors

Secondary Listing of Qualifying Issuers

GRANDFATHERED GREATER CHINA COMPANIES **NON-GRANDFATHERED** GREATER CHINA COMPANIES

NON-GREATER CHINA COMPANIES

NON-GRANDFATHERED GREATER CHINA COMPANIES:

- Greater China companies that primary listed on a Qualifying Exchange <u>after 15 Dec 2017</u>
- Must vary constitutional documents as required by existing Rules to meet "equivalence" requirements
- No need to comply with ongoing primary Listing Rule requirements (e.g. notifiable transaction and connected transaction rules)
- WVR structures and VIE structures (if they have them) must conform to all primary Listing Rule requirements
- If "bulk of trading" moves permanently to Hong Kong then primary Listing Rule requirements would apply
- Approach designed to deter "regulatory arbitrage"



Secondary Listing of Qualifying Issuers

GRANDFATHERED GREATER CHINA COMPANIES **NON-GRANDFATHERED** GREATER CHINA COMPANIES NON-GREATER CHINA COMPANIES


NON-GREATER CHINA COMPANIES:

- Any company from outside of Greater China primary listed on a Qualifying Exchange
- Must demonstrate how they are subject to Key Shareholder Protections⁽¹⁾ (changes to constitutional documents may be required, as necessary)
- No need to comply with ongoing primary Listing Rule requirements (e.g. notifiable transaction and connected transaction rules)
- Can secondary list with their existing WVR structures and VIE structures intact (if they have them)
- No need for them to comply with WVR safeguards (other than those requiring disclosure)
- No change if "bulk of trading" moves permanently to Hong Kong



(1) For example:

- issuer must hold an annual general meeting at least every 15 months, give reasonable notice of meetings and members to have the right to speak and vote at the shareholders' meeting
- super-majority vote of members is required to approve fundamental matters (material changes to constitutional documents, variation of rights attached to any class of shares and voluntary winding-up)
- appointment, removal and the remuneration of auditors require the approval of a majority of shareholders or other body independent of the board of directors



TIMETABLE AND NEXT STEPS







HKEX invites market views on the proposals and the Listing Rules to implement them





